Cargando…

The Edmonton Classification System for Cancer Pain in Patients with Bone Metastasis: a descriptive cohort study

PURPOSE: We describe the prevalence of the Edmonton Classification System for Cancer Pain (ECS-CP) features in patients with bone metastasis and cancer-induced bone pain (CIBP) and the relationship between ECS-CP features, pain intensity, and opioid consumption. METHODS: We assessed ECS-CP features...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulistio, Merlina, Ling, Natalie, Finkelstein, Tara, Tee, Hoong Jiun, Gorelik, Alexandra, Kissane, David, Michael, Natasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140090/
https://www.ncbi.nlm.nih.gov/pubmed/37106261
http://dx.doi.org/10.1007/s00520-023-07711-9
_version_ 1785033089186004992
author Sulistio, Merlina
Ling, Natalie
Finkelstein, Tara
Tee, Hoong Jiun
Gorelik, Alexandra
Kissane, David
Michael, Natasha
author_facet Sulistio, Merlina
Ling, Natalie
Finkelstein, Tara
Tee, Hoong Jiun
Gorelik, Alexandra
Kissane, David
Michael, Natasha
author_sort Sulistio, Merlina
collection PubMed
description PURPOSE: We describe the prevalence of the Edmonton Classification System for Cancer Pain (ECS-CP) features in patients with bone metastasis and cancer-induced bone pain (CIBP) and the relationship between ECS-CP features, pain intensity, and opioid consumption. METHODS: We assessed ECS-CP features and recoded pain mechanisms and opioid use in adult patients with bone metastasis. Validated measures were used to assess pain intensity, incident pain, psychological distress, addictive behavior, and cognition. RESULTS: Among 147 eligible patients, 95.2% completed the assessment. Mean participant age was 73.2 years, the majority female (52.1%) with breast cancer occurring most commonly (25.7%). One or more ECS-CP features were present in 96.4% and CIBP in 75.7% of patients. The median average and worst pain scores were 3 and 6, respectively. Neuropathic pain was the most prevalent pain mechanism (45.0%) and was associated with breakthrough pain frequency (p=0.014). Three-quarters had incident pain, which was strongly associated with a higher average and worst pain scores (3.5 and 7, p<0.001 for both), background oral morphine equivalent daily dose (26.7mg, p=0.005), and frequency of daily breakthrough analgesia (1.7 doses/day, p=0.007). Psychological distress (n=90, 64.3%) was associated with a significantly higher average pain score (4, p=0.009) and a slightly higher worst pain score (7, p=0.054). Addictive behaviour and cognitive dysfunction were relatively uncommon (18.6% and 12.9%, respectively). CONCLUSION: There is a need to promote standardized assessment and classification of pain syndromes such as CIBP. The ECS-CP may allow us to consider CIBP in a systematic manner and develop personalized pain interventions appropriate to the pain profile. TRIAL REGISTRATION: Retrospectively registered in ANZCTR ACTRN12622000853741 (16/06/2022) SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-023-07711-9.
format Online
Article
Text
id pubmed-10140090
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101400902023-04-29 The Edmonton Classification System for Cancer Pain in Patients with Bone Metastasis: a descriptive cohort study Sulistio, Merlina Ling, Natalie Finkelstein, Tara Tee, Hoong Jiun Gorelik, Alexandra Kissane, David Michael, Natasha Support Care Cancer Research PURPOSE: We describe the prevalence of the Edmonton Classification System for Cancer Pain (ECS-CP) features in patients with bone metastasis and cancer-induced bone pain (CIBP) and the relationship between ECS-CP features, pain intensity, and opioid consumption. METHODS: We assessed ECS-CP features and recoded pain mechanisms and opioid use in adult patients with bone metastasis. Validated measures were used to assess pain intensity, incident pain, psychological distress, addictive behavior, and cognition. RESULTS: Among 147 eligible patients, 95.2% completed the assessment. Mean participant age was 73.2 years, the majority female (52.1%) with breast cancer occurring most commonly (25.7%). One or more ECS-CP features were present in 96.4% and CIBP in 75.7% of patients. The median average and worst pain scores were 3 and 6, respectively. Neuropathic pain was the most prevalent pain mechanism (45.0%) and was associated with breakthrough pain frequency (p=0.014). Three-quarters had incident pain, which was strongly associated with a higher average and worst pain scores (3.5 and 7, p<0.001 for both), background oral morphine equivalent daily dose (26.7mg, p=0.005), and frequency of daily breakthrough analgesia (1.7 doses/day, p=0.007). Psychological distress (n=90, 64.3%) was associated with a significantly higher average pain score (4, p=0.009) and a slightly higher worst pain score (7, p=0.054). Addictive behaviour and cognitive dysfunction were relatively uncommon (18.6% and 12.9%, respectively). CONCLUSION: There is a need to promote standardized assessment and classification of pain syndromes such as CIBP. The ECS-CP may allow us to consider CIBP in a systematic manner and develop personalized pain interventions appropriate to the pain profile. TRIAL REGISTRATION: Retrospectively registered in ANZCTR ACTRN12622000853741 (16/06/2022) SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-023-07711-9. Springer Berlin Heidelberg 2023-04-28 2023 /pmc/articles/PMC10140090/ /pubmed/37106261 http://dx.doi.org/10.1007/s00520-023-07711-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Sulistio, Merlina
Ling, Natalie
Finkelstein, Tara
Tee, Hoong Jiun
Gorelik, Alexandra
Kissane, David
Michael, Natasha
The Edmonton Classification System for Cancer Pain in Patients with Bone Metastasis: a descriptive cohort study
title The Edmonton Classification System for Cancer Pain in Patients with Bone Metastasis: a descriptive cohort study
title_full The Edmonton Classification System for Cancer Pain in Patients with Bone Metastasis: a descriptive cohort study
title_fullStr The Edmonton Classification System for Cancer Pain in Patients with Bone Metastasis: a descriptive cohort study
title_full_unstemmed The Edmonton Classification System for Cancer Pain in Patients with Bone Metastasis: a descriptive cohort study
title_short The Edmonton Classification System for Cancer Pain in Patients with Bone Metastasis: a descriptive cohort study
title_sort edmonton classification system for cancer pain in patients with bone metastasis: a descriptive cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140090/
https://www.ncbi.nlm.nih.gov/pubmed/37106261
http://dx.doi.org/10.1007/s00520-023-07711-9
work_keys_str_mv AT sulistiomerlina theedmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT lingnatalie theedmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT finkelsteintara theedmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT teehoongjiun theedmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT gorelikalexandra theedmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT kissanedavid theedmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT michaelnatasha theedmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT sulistiomerlina edmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT lingnatalie edmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT finkelsteintara edmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT teehoongjiun edmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT gorelikalexandra edmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT kissanedavid edmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy
AT michaelnatasha edmontonclassificationsystemforcancerpaininpatientswithbonemetastasisadescriptivecohortstudy